Monoamine Oxidases and their Inhibitors

Monoamine Oxidases and their Inhibitors

1st Edition - October 5, 2011

Write a review

  • Editors: Moussa Youdim, Peter Riederer
  • Hardcover ISBN: 9780123864673
  • eBook ISBN: 9780123864680

Purchase options

Purchase options
Available
DRM-free (Mobi, EPub, PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. In this volume, invited experts provide authoritative reviews on various aspects of Monoamine Oxidase and its Inhibitors.

Key Features

  • Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research
  • Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered
  • All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist

Readership

Neuroscientists, Neurologists, Neurobiologists

Table of Contents

  • CONTRIBUTORS

    PREFACE

    STRUCTURAL PROPERTIES OF HUMAN MONOAMINE OXIDASES A AND B

    I. Introduction

    II. Crystallization of Purified MAO-B and MAO-A

    III. Structure of Human MAO-B

    IV. Structure of Human MAO-A and Comparison with Rat MAO-A

    V. Insights into Membrane Binding of MAO-A and MAO-B

    VI. Structural Basis for Inhibitor-Binding Specificities of MAO-A and MAO-B

    VII. Conclusions and Future Prospects

    BEHAVIORAL OUTCOMES OF MONOAMINE OXIDASE DEFICIENCY: PRECLINICAL AND CLINICAL EVIDENCE

    I. General Characteristics of Monoamine Oxidase

    II. Phenotypical Outcomes of MAO-A Deficit

    III. Phenotypical Outcomes of MAO-B Deficit

    IV. Phenotypical Outcomes of Combined MAO-A and MAO-B Deficit

    V. Conclusions

    KINETIC BEHAVIOR AND REVERSIBLE INHIBITION OF MONOAMINE OXIDASES—ENZYMES THAT MANY WANT DEAD

    I. Introduction

    II. Some Basics of Enzyme Inhibition

    III. Systems Behavior of Reversible Inhibitors

    IV. How Can Kinetic Studies of MAO Help?

    V. Tight-Binding Inhibitors

    VI. Recovery from Inhibition

    VII. Conclusions

    THE PHARMACOLOGY OF SELEGILINE

    I. Historical Aspects of Selegiline

    II. The Multiplicity of Monoamine Oxidase

    III. The Pharmacology of MAO-B Inhibition

    IV. Structure–Activity Relationship Studies

    V. Effects of Selegiline Not Relating to MAO-B Inhibition

    VI. Antiapoptotic Effect of Selegiline

    VII. Pharmacokinetics of Selegiline

    VIII. Metabolism of Selegiline

    IX. The Role of Birkmayer and His Group in the Introduction of Selegiline in the Therapy of Parkinson’s Disease

    X. Future Perspectives

    XI. Overall Conclusions

    TYPE A MONOAMINE OXIDASE REGULATES LIFE AND DEATH OF NEURONS IN NEURODEGENERATION AND NEUROPROTECTION

    I. Introduction

    II. Type A and B MAO in Cell Death of Neurons

    III. MAO-A in Neuroprotection by MAO-Is

    IV. MAO-A in Induction of Neurotrophic Factors by MAO-Is

    V. Is MAO-A the Binding Site of MAO-Is for Induction of Neuroprotective Genes?

    VI. Signal Pathway for Induction of Prosurvival Genes by MAO-Is

    VII. Discussion

    MULTIMODAL DRUGS AND THEIR FUTURE FOR ALZHEIMER’S AND PARKINSON’S DISEASE

    I. Introduction

    II. Concepts in Multimodal Drug Design

    III. Monoamine Oxidase as a Common Target in AD and PD

    IV. Multimodal Drugs That Target MAO (1)

    V. Multimodal Drugs That Target MAO (2)

    VI. Multimodal Drugs That Target MAO (3)

    VII. Multimodal Drugs That Target Memory and Neurogenesis

    VIII. Conclusion

    NEUROPROTECTIVE PROFILE OF THE MULTITARGET DRUG RASAGILINE IN PARKINSON’S DISEASE

    I. Introduction

    II. Multiple Activities of Rasagiline

    III. The Major Metabolite of Rasagiline, 1-(R)-Aminoindan

    IV. Summary and Conclusions

    RASAGILINE IN PARKINSON’S DISEASE

    I. Introduction

    II. In Vivo and In Vitro Neuroprotective Effects of Rasagiline

    III. Pharmacokinetics and Pharmacodynamics

    IV. Evidence for the Symptomatic Benefits of Rasagiline in PD

    V. Evidence for Disease Modification with Rasagiline in PD

    VI. Adverse Effects

    VII. Conclusion

    SELECTIVE INHIBITORS OF MONOAMINE OXIDASE TYPE B AND THE “CHEESE EFFECT”

    I. Introduction

    II. Pharmacology of Tyramine

    III. Mechanism of “Cheese Effect”

    IV. Cardiovascular Actions of Tyramine

    V. Selegiline

    VI. Clinical Use of Selegiline and Cheese Effect

    VII. Clinical Use of Rasagiline and Cheese Effect

    VIII. Reversible Inhibitors of MAO-B

    IX. Modification of L-Dopa Cardiovascular Response by Selective Inhibitors of MAO-B

    X. Tyramine Content in Foods

    XI. Treatment of Cheese Reaction

    XII. Specific Foods

    XIII. Fish Sauces

    XIV. Meat

    XV. Beer and Wine

    XVI. Conclusions

    A NOVEL ANTI-ALZHEIMER’S DISEASE DRUG, LADOSTIGIL

    I. Introduction

    II. The Underlying Strategy in the Design of Ladostigil

    III. MAO Inhibition and Antidepressant Activity of Ladostigil

    IV. ChE Inhibitory Activity of Ladostigil

    V. Neuroprotective Activities of Ladostigil in Preclinical Models of Neurodegeneration

    VI. Mechanism of Action of Ladostigil

    VII. Summary and Future Perspectives

    NOVEL MAO-B INHIBITORS

    I. Introduction

    II. MAO-B Inhibitors

    III. Apoptosis in PD

    IV. Clinical Potential of PF9601N

    V. Concluding Remarks

    Subject Index

    Contents of recent volumes

Product details

  • No. of pages: 320
  • Language: English
  • Copyright: © Academic Press 2011
  • Published: October 5, 2011
  • Imprint: Academic Press
  • Hardcover ISBN: 9780123864673
  • eBook ISBN: 9780123864680

About the Serial Volume Editors

Moussa Youdim

Affiliations and Expertise

Eve Topf Centre of Excellence for Neurodegenerative Diseases, Hafia, Israel

Peter Riederer

Affiliations and Expertise

University of Wurzburg, Germany

Ratings and Reviews

Write a review

There are currently no reviews for "Monoamine Oxidases and their Inhibitors"